For the year ending 2025-12-31, CORT had -$7,170K decrease in cash & cash equivalents over the period. $141,785K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 99,652 |
| Stock-based compensation | 84,500 |
| Accretion of discount on marketable securities, net | 5,103 |
| Depreciation and amortization | 1,149 |
| Deferred income taxes | -37,537 |
| Amortization of right-of-use asset | 741 |
| Trade receivables | 5,810 |
| Insurance recovery receivable related to melucci litigation (note 10) | 0 |
| Inventory | 7,481 |
| Prepaid expenses and other current assets | 18,917 |
| Other assets | -1,457 |
| Accounts payable | 25,068 |
| Accrued research and development expenses | 86 |
| Accrued and other liabilities | 3,928 |
| Accrued settlement related to melucci litigation (note 10) | 0 |
| Long-term accrued income taxes | 1,092 |
| Operating lease liability | -829 |
| Net cash provided by operating activities | 141,996 |
| Purchases of property and equipment | 211 |
| Proceeds from maturities of marketable securities | 389,576 |
| Purchases of marketable securities | 319,607 |
| Net cash provided (used in) by investing activities | 69,758 |
| Proceeds from stock option exercises, net of issuance costs | 15,869 |
| Proceeds from purchases under the employee stock purchase program | 9,621 |
| Repurchases of common stock in connection with stock repurchase program | 172,915 |
| Repurchase of common stock in connection with tender offer | 0 |
| Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants | 72,941 |
| Net cash used in financing activities | -220,366 |
| Net effect of exchange rate changes on cash and cash equivalents | 1,442 |
| Net (decrease) increase in cash and cash equivalents | -7,170 |
| Cash and cash equivalents, at beginning of period | 127,665 |
| Cash and cash equivalents, at end of period | 120,495 |
CORCEPT THERAPEUTICS INC (CORT)
CORCEPT THERAPEUTICS INC (CORT)